Prospective, Double-Blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of Latiglutenase Treatment in Type 1 Diabetes Patients With Celiac Disease While Undergoing Periodic Gluten Exposure
Latest Information Update: 07 Aug 2024
At a glance
- Drugs Latiglutenase (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- Sponsors ImmunogenX
- 18 Jul 2023 Status changed from recruiting to discontinued.
- 02 Aug 2022 Planned number of patients changed from 30 to 40.
- 02 Aug 2022 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.